Protalix BioTherapeutics (PLX) Current Leases (2019 - 2026)

Protalix BioTherapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Current Leases rose 0.56% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (up 0.56% YoY), while the FY2025 annual figure was $1.4 million, down 7.73% from the prior year.
• Current Leases was $1.4 million for Q1 2026 at Protalix BioTherapeutics, up from $1.4 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.5 million in Q3 2024 to a low of $1.0 million in Q3 2022.
• Historically, Current Leases has averaged $1.3 million across 5 years, with a median of $1.4 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Current Leases dropped 19.03% in 2022, then soared 31.3% in 2023.
• A 5-year view of Current Leases shows it stood at $1.1 million in 2022, then gained by 26.03% to $1.4 million in 2023, then grew by 6.46% to $1.5 million in 2024, then declined by 7.73% to $1.4 million in 2025, then increased by 3.54% to $1.4 million in 2026.
• The last three Current Leases figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.